Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up

These long-term results show that Bor-HDM is a safe and effective option for ASCT conditioning regimens.

Authors

Institutions

Publication Details

Journal
In Vivo
Published
2024-12-31
DOI
https://doi.org/10.21873/invivo.13833
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up

Toshiya Kagoo, Risa Nishiyama, Akihiro Yokoyama, Hironori Ueno
1 links
In Vivo
Multiple Myeloma Research and Treatments
article

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up

Toshiya Kagoo, Risa Nishiyama, Akihiro Yokoyama, Hironori Ueno
article en

Abstract

These long-term results show that Bor-HDM is a safe and effective option for ASCT conditioning regimens.

In VivoVol. 39(1)
Tokyo Medical Center (JP), National Hospital Organization (JP), Tokyo National Hospital (JP)
Good health and well-being
Openalex Percentile: Top 55%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up — Toshiya Kagoo, Risa Nishiyama, et al. · In Vivo (2024) | TGRS Research Map | TGRS